Welcome to our dedicated page for Puma Biotechnology news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on Puma Biotechnology stock.
Puma Biotechnology Inc (PBYI) is a biopharmaceutical company focused on advancing targeted therapies for cancer treatment, including its commercialized product NERLYNX® (neratinib) for HER2-positive breast cancer. This page provides investors and healthcare professionals with a comprehensive repository of official company announcements and verified news updates.
Access timely information about clinical trial developments, regulatory milestones, and strategic partnerships directly from the source. Our curated collection includes earnings reports, research advancements, and manufacturing updates related to PBYI's oncology portfolio, including updates on alisertib's development as an aurora kinase A inhibitor.
All content is organized chronologically to help track the company's progress in bringing innovative cancer therapies to market through its risk-mitigated in-licensing strategy. Bookmark this page for convenient access to primary source information about PBYI's contributions to precision medicine in oncology care.
Puma Biotechnology (NASDAQ: PBYI) announced the titles of abstracts for neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. Key studies include the SUMMIT trial on neratinib with fulvestrant and trastuzumab for HR+, HER2-negative, HER2-mutant metastatic breast cancer, and targeting HER2 mutation-positive advanced biliary tract cancers. Full abstracts will be available online on May 26.
Puma Biotechnology (NASDAQ: PBYI) will host a conference call on May 5, 2022, at 1:30 p.m. PDT to discuss its Q1 2022 financial results. Interested parties can join the call by dialing (866) 682-6100 domestically or (862) 298-0702 internationally, and are advised to call in 10 minutes early. A live webcast will be available on the company’s website, and a replay will be archived for 90 days. Puma focuses on innovative cancer care products and is known for its oral neratinib, approved by the FDA for breast cancer treatment.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on April 1, 2022, the grant of 31,875 inducement restricted stock unit awards to four new non-executive employees. These awards, approved by the Compensation Committee, will vest over three years, with one-third vesting after one year and the remainder in six-month intervals. This initiative is part of Puma's 2017 Employment Inducement Incentive Award Plan and complies with Nasdaq Listing Rule 5635(c)(4).
Puma focuses on innovative cancer care solutions, including the marketed product NERLYNX®.
Puma Biotechnology (Nasdaq: PBYI) announced a private placement agreement to sell 3,584,228 shares at $2.79 each, totaling around $10 million. The deal involves CEO Alan Auerbach and Athyrium Capital Management. The funds will be used for general corporate purposes and the closing is expected by March 10, 2022, pending customary conditions. The shares are not registered under the Securities Act, but Puma plans to file a registration statement for their resale.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that
Puma Biotechnology (NASDAQ: PBYI) announced on March 1, 2022, the approval of an inducement restricted stock unit award for 9,375 shares to a new non-executive employee. This award, part of Puma’s 2017 Employment Inducement Incentive Award Plan, vests over three years, with a third vesting on the first anniversary and one-sixth every six months thereafter, contingent on continued service. The grant complies with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for the new hire.
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported its financial results for Q4 and the full year 2021. The company generated $51.0 million in product revenue for Q4 2021, a slight increase from $50.0 million in Q4 2020, while full-year product revenue fell to $189.1 million from $196.7 million. Puma achieved a net income of $4.2 million in Q4 2021 versus a net loss of $15.0 million in Q4 2020. Total revenue for 2021 was $253.2 million, an increase from $225.1 million in 2020. The company expects key milestones in the coming year related to its HER2-positive breast cancer treatment.
Puma Biotechnology, Inc. (NASDAQ: PBYI) will hold a conference call on Thursday, March 3, at 1:30 p.m. PST/4:30 p.m. EST to discuss its fourth quarter and full year 2021 financial results. Investors can participate by calling 1-877-709-8150 (domestic) or 1-201-689-8354 (international). A live webcast and presentation slides will be available on Puma's website. The replay will be accessible one hour after the call for 90 days. Puma focuses on developing innovative cancer treatments, including its FDA-approved drug, NERLYNX® (neratinib), for HER2-positive breast cancer.
Puma Biotechnology (NASDAQ: PBYI) has announced the approval of inducement restricted stock unit awards for three new non-executive employees on February 1, 2022. A total of 24,375 shares will be awarded under the 2017 Employment Inducement Incentive Award Plan, with shares vesting over three years. One-third will vest after one year, and one-sixth will vest every six months thereafter, contingent on continued service. This grant complies with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent joining the company.
Puma Biotechnology (NASDAQ: PBYI) announced on January 18, 2022, that its Board's Compensation Committee approved the grant of a restricted stock unit award covering 11,250 shares to a new non-executive employee. This award, part of Puma’s 2017 Employment Inducement Incentive Award Plan, vests over three years, with one-third vesting on the first anniversary of the vesting commencement date (January 1, 2022). The award was granted in accordance with Nasdaq Listing Rule 5635(c)(4), facilitating the employee's entry into the company.
FAQ
What is the current stock price of Puma Biotechnology (PBYI)?
What is the market cap of Puma Biotechnology (PBYI)?
